Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

ASH 2024 Summary: FL Highlights

2024 ASH Annual Meeting Insights Hub

P. Strati

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

ASH 2025 Review: Updates in Frontline & R/R DLBCL

University of Colorado Division of Hematology

M. Kamdar

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

Treating Patients With DLBCL Who Are Not Eligible for CAR-T Therapy

Remy Dulery

Sequencing Cellular Therapy and Bispecific Antibodies in DLBCL

Megan Melody

FDA Approval of Acalabrutinib + BR for 1L MCL: Ph3 ECHO Trial & Subg…

Chan Cheah

Steroid-Refractory GVHD Updates

Roswell Park Comprehensive Cancer Center

S. Holtan

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

ASH 2024 Insights: Outcomes With Bispecific Antibodies Post-CAR T-Ce…

2024 ASH Annual Meeting Insights Hub

M. Melody

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Updates on Approved CAR-Ts for Lymphomas

Moffitt Cancer Center

J. Chavez

Tandem 2025 Insights: PTCy-Based GVHD Prophylaxis After Mismatched U…

Insights from 2025 Tandem Annual Meeting

M. Al Malki

Tafasitamab + Lenalidomide in R/R DLBCL: Updated Results From the L-…

David Bond

FL: How Do I Deal With Relapse?

SOHO Brazil 2024

B. Kahl

ASH 2024 Insights: Timing of CAR-T Failure as a Predictor of Outcome…

2024 ASH Annual Meeting Insights Hub

E. Shumilov